Alternative cancer therapy for Thyroid cancer
In 2019, around 235,300 women and 197,600 men developed thyroid cancer. The mean age of onset was 49 years for women and 53 years for men. Thyroid cancer death rates decreased worldwide between 2004 and 2019 for both men and women. At the same time, the age-standardized incidence rates rose in both. However, the only contribution to this was made by the prognostically very favorable papillary carcinomas, the most common histological type in both sexes. Mostly people up to the age of 60 are affected by this increase. Most thyroid cancer is diagnosed at an early stage. The proportion of women here is 73 percent and of men 56 percent. With the relative five-year survival rate, women have an even more favorable prognosis (89 percent) than men (84 percent).
With the help of our Thyroid cancer enzyme, the spread and growth of malignant tumors can be slowed down in a targeted manner.
We recommend taking one capsule twice a day.
